Clinical Trial

AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This trial is a Phase III study. All patients are stage IIIB/C (unsuitable for radical therapy) or stage IV squamous non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of AK112 combined with chemotherapy versus Tislelizumab combined with chemotherapy in patients with advanced squamous NSCLC.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-04-21; most recent amendment 2025-04-30.
Status change: Recruiting → Active, Not Recruiting 2025-04-30
Status change: Not Yet Recruiting → Recruiting 2023-08-22
Trial Details
NCT Number NCT05840016
Lead Sponsor Akeso
Conditions Advanced Squamous Non Small Cell Lung Cancer
Enrollment 532 participants
Start Date 2023-08-17
Primary Completion 2025-02-28 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-05-02